首页> 美国卫生研究院文献>Advances in Hematology >Haploidentical Stem Cell Transplantation in Adult Haematological Malignancies
【2h】

Haploidentical Stem Cell Transplantation in Adult Haematological Malignancies

机译:成人血液学恶性肿瘤的单倍体干细胞移植。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Haematopoietic stem cell transplantation is a well-established treatment option for both hematological malignancies and nonmalignant conditions such as aplastic anemia and haemoglobinopathies. For those patients lacking a suitable matched sibling or matched unrelated donor, haploidentical donors are an alternative expedient donor pool. Historically, haploidentical transplantation led to high rates of graft rejection and GVHD. Strategies to circumvent these issues include T cell depletion and management of complications thereof or T replete transplants with GVHD prophylaxis. This review is an overview of these strategies and contemporaneous outcomes for hematological malignancies in adult haploidentical stem cell transplant recipients.
机译:造血干细胞移植是血液系统恶性肿瘤和非恶性疾病(如再生障碍性贫血和血红蛋白病)的公认治疗方案。对于那些缺少合适的同胞匹配或无亲属供体的患者,单倍体供体是替代的权宜之计。从历史上看,单倍体移植导致移植排斥和GVHD发生率很高。规避这些问题的策略包括T细胞耗竭及其并发症的处理或预防GVHD的T充足性移植。这篇综述概述了成人单倍体干细胞移植受者血液学恶性肿瘤的这些策略和同期结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号